Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

Q1 2026 Earnings Call Transcript August 13, 2025 Aethlon Medical, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.68. Operator: Good afternoon, and welcome to ...

Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the ...

Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Discover insights into Aethlon Medical's Q1 2026 earnings as they advance their Australian oncology trial, cut costs by 32%, and focus on ...